Expression of pepsinogen II in gastric cancer. Its relationship to local invasion and lymph node metastases

R. Fiocca, M. Cornaggia, L. Villani, C. Capella, E. Solcia, I. M. Samloff

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We have determined the prevalence of pepsinogen II (PG II) immunoreactive cells in a large series of early and advanced gastric cancers and relationships among PG II-positivity, tumor histologic type, extent of gastric wall invasion, and presence of lymph node metastases. Of the 316 cancers evaluated, 150 (47%) expressed PG II. The prevalence by histologic type was 55% in 146 glandular tumors, 43% in 83 diffuse tumors, 16% in 25 mucoid tumors, and 51% in 59 mixed-type cancers. Two parietal cell cancers and one undifferentiated cancer were PG II-negative. In glandular and diffuse cancers, but not mucoid and mixed tumors, both the extent of gastric wall invasion and indicence of lymph node metastases were associated positively with PG II expression by the primary tumor. In particular, PG II-reactive cells were found significantly more often in advanced than in early diffuse cancers (P <0.05) and significantly more often in submucosal early cancers than in intramucosal early cancers (P <0.01). The prevalence of PG II expression also was higher significantly in metastatic cancers than in nonmetastatic cancers. This was true for advanced gastric cancers as a whole (P <0.01), advanced glandular-type cancer alone (P <0.01), advanced glandular- and diffuse- type cancers together (P <0.001), and early diffuse-type cancer (P <0.05). Only four (3%) of 145 cancers evaluated for pepsinogen I (PG I) were positive, and each also was positive for PG II. The results suggest that the expression of PG II by glandular and diffuse types of gastric cancer may be a marker of increased malignancy.

Original languageEnglish
Pages (from-to)956-962
Number of pages7
JournalCancer
Volume61
Issue number5
Publication statusPublished - 1988

Fingerprint

Pepsinogen C
Stomach Neoplasms
Lymph Nodes
Neoplasm Metastasis
Neoplasms
Stomach

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of pepsinogen II in gastric cancer. Its relationship to local invasion and lymph node metastases. / Fiocca, R.; Cornaggia, M.; Villani, L.; Capella, C.; Solcia, E.; Samloff, I. M.

In: Cancer, Vol. 61, No. 5, 1988, p. 956-962.

Research output: Contribution to journalArticle

@article{08ea3af9e4954808bdd4847a4253dcc3,
title = "Expression of pepsinogen II in gastric cancer. Its relationship to local invasion and lymph node metastases",
abstract = "We have determined the prevalence of pepsinogen II (PG II) immunoreactive cells in a large series of early and advanced gastric cancers and relationships among PG II-positivity, tumor histologic type, extent of gastric wall invasion, and presence of lymph node metastases. Of the 316 cancers evaluated, 150 (47{\%}) expressed PG II. The prevalence by histologic type was 55{\%} in 146 glandular tumors, 43{\%} in 83 diffuse tumors, 16{\%} in 25 mucoid tumors, and 51{\%} in 59 mixed-type cancers. Two parietal cell cancers and one undifferentiated cancer were PG II-negative. In glandular and diffuse cancers, but not mucoid and mixed tumors, both the extent of gastric wall invasion and indicence of lymph node metastases were associated positively with PG II expression by the primary tumor. In particular, PG II-reactive cells were found significantly more often in advanced than in early diffuse cancers (P <0.05) and significantly more often in submucosal early cancers than in intramucosal early cancers (P <0.01). The prevalence of PG II expression also was higher significantly in metastatic cancers than in nonmetastatic cancers. This was true for advanced gastric cancers as a whole (P <0.01), advanced glandular-type cancer alone (P <0.01), advanced glandular- and diffuse- type cancers together (P <0.001), and early diffuse-type cancer (P <0.05). Only four (3{\%}) of 145 cancers evaluated for pepsinogen I (PG I) were positive, and each also was positive for PG II. The results suggest that the expression of PG II by glandular and diffuse types of gastric cancer may be a marker of increased malignancy.",
author = "R. Fiocca and M. Cornaggia and L. Villani and C. Capella and E. Solcia and Samloff, {I. M.}",
year = "1988",
language = "English",
volume = "61",
pages = "956--962",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Expression of pepsinogen II in gastric cancer. Its relationship to local invasion and lymph node metastases

AU - Fiocca, R.

AU - Cornaggia, M.

AU - Villani, L.

AU - Capella, C.

AU - Solcia, E.

AU - Samloff, I. M.

PY - 1988

Y1 - 1988

N2 - We have determined the prevalence of pepsinogen II (PG II) immunoreactive cells in a large series of early and advanced gastric cancers and relationships among PG II-positivity, tumor histologic type, extent of gastric wall invasion, and presence of lymph node metastases. Of the 316 cancers evaluated, 150 (47%) expressed PG II. The prevalence by histologic type was 55% in 146 glandular tumors, 43% in 83 diffuse tumors, 16% in 25 mucoid tumors, and 51% in 59 mixed-type cancers. Two parietal cell cancers and one undifferentiated cancer were PG II-negative. In glandular and diffuse cancers, but not mucoid and mixed tumors, both the extent of gastric wall invasion and indicence of lymph node metastases were associated positively with PG II expression by the primary tumor. In particular, PG II-reactive cells were found significantly more often in advanced than in early diffuse cancers (P <0.05) and significantly more often in submucosal early cancers than in intramucosal early cancers (P <0.01). The prevalence of PG II expression also was higher significantly in metastatic cancers than in nonmetastatic cancers. This was true for advanced gastric cancers as a whole (P <0.01), advanced glandular-type cancer alone (P <0.01), advanced glandular- and diffuse- type cancers together (P <0.001), and early diffuse-type cancer (P <0.05). Only four (3%) of 145 cancers evaluated for pepsinogen I (PG I) were positive, and each also was positive for PG II. The results suggest that the expression of PG II by glandular and diffuse types of gastric cancer may be a marker of increased malignancy.

AB - We have determined the prevalence of pepsinogen II (PG II) immunoreactive cells in a large series of early and advanced gastric cancers and relationships among PG II-positivity, tumor histologic type, extent of gastric wall invasion, and presence of lymph node metastases. Of the 316 cancers evaluated, 150 (47%) expressed PG II. The prevalence by histologic type was 55% in 146 glandular tumors, 43% in 83 diffuse tumors, 16% in 25 mucoid tumors, and 51% in 59 mixed-type cancers. Two parietal cell cancers and one undifferentiated cancer were PG II-negative. In glandular and diffuse cancers, but not mucoid and mixed tumors, both the extent of gastric wall invasion and indicence of lymph node metastases were associated positively with PG II expression by the primary tumor. In particular, PG II-reactive cells were found significantly more often in advanced than in early diffuse cancers (P <0.05) and significantly more often in submucosal early cancers than in intramucosal early cancers (P <0.01). The prevalence of PG II expression also was higher significantly in metastatic cancers than in nonmetastatic cancers. This was true for advanced gastric cancers as a whole (P <0.01), advanced glandular-type cancer alone (P <0.01), advanced glandular- and diffuse- type cancers together (P <0.001), and early diffuse-type cancer (P <0.05). Only four (3%) of 145 cancers evaluated for pepsinogen I (PG I) were positive, and each also was positive for PG II. The results suggest that the expression of PG II by glandular and diffuse types of gastric cancer may be a marker of increased malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0023858894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023858894&partnerID=8YFLogxK

M3 - Article

C2 - 3338059

AN - SCOPUS:0023858894

VL - 61

SP - 956

EP - 962

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -